FDA's Marty Makary on Over-the-Counter Drugs, mRNA Vaccines, and Clinical Trial Reform

Regulating GLP-1 Compounding

• 🎯 The FDA is taking decisive steps to crack down on unlawful mass compounding of GLP-1 drugs, targeting companies that violate regulations for API importation and marketing claims.
• ⚖️ Companies that properly undergo FDA processes, including phase trials and demonstrating benefits, are regulated in marketing and adverse event reporting.
• 🤝 The goal is to ensure a level playing field where competition is fair and companies adhere to established rules.

mRNA Technology and Vaccine Guidance

• 💉 The FDA's refusal to file for Moderna's mRNA flu vaccine application signals a need for clear guidance, especially regarding the control group's standard of care.
• ⚠️ Concerns exist that using substandard care in control groups, particularly for those over 65, unnecessarily exposes them to higher influenza complication risks.
• 📈 While optimistic about mRNA technology's potential in vaccines, cancer, and other infectious diseases, the FDA emphasizes that all products must meet rigorous scientific standards and be reviewed based on data.

Expanding Over-the-Counter Medications

• 💡 Dr. Makary advocates for a shift towards making more drugs available over-the-counter, questioning why certain medications like vaginal estrogen, nausea medication, and naloxone require prescriptions.
• 💰 This initiative aims to lower drug prices through increased price transparency and competition, contrasting with complex insurance co-pays.
• 🚀 The FDA is working through regulatory processes to change monographs and streamline the transition of safe medications to OTC status, challenging the current onerous bureaucratic process.

Reforming Clinical Trials and US Competitiveness

• 📉 The US faces a challenge with China conducting significantly more phase one clinical trials, necessitating major reforms to bring trials back to the United States.
• ⚙️ Key areas for reform include streamlining hospital contracting and Institutional Review Board (IRB) approval processes, which are currently clunky and time-consuming.
• ⏱️ Reducing the pre-IND to IND process timeline, currently averaging 520 days in the US compared to China's under 200 days, is crucial for competitiveness.
• 🤝 The FDA aims to move away from a purely regulatory stance to a partnership with industry to accelerate the delivery of cures and treatments by cutting red tape and asking fewer, more relevant questions.